Easterly Investment Partners’s Pacira BioSciences PCRX Stock Holding History

Easterly Investment Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.55M	Buy	337,019 +2,165	+0.6%	+$51.2K	0.44%	47
2026 Q1	$7.66M	Buy	334,854 +83,000	+33%	+$1.84M	0.59%	48
2025 Q4	$6.52M	Buy	251,854 +2,745	+1%	+$65.3K	0.4%	66
2025 Q3	$6.42M	Buy	249,109 +79,038	+46%	+$1.94M	0.43%	68
2025 Q2	$4.06M	Buy	170,071 +57,900	+52%	+$1.46M	0.29%	86
2025 Q1	$2.79M	Buy	112,171 +6,520	+6%	+$156K	0.23%	97
2024 Q4	$1.99M	Sell	105,651 -28,833	-21%	-$506K	0.16%	116
2024 Q3	$2.02M	Buy	134,484 +28,928	+27%	+$495K	0.16%	118
2024 Q2	$3.02M	Buy	105,556 +26,235	+33%	+$747K	0.27%	95
2024 Q1	$2.32M	Buy	79,321 +23,877	+43%	+$734K	0.18%	112
2023 Q4	$1.87M	Buy	55,444 +17,594	+46%	+$515K	0.2%	113
2023 Q3	$1.16M	Buy	+37,850	New	+$1.36M	0.13%	127

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Easterly Investment Partners's PCRX Position: Q2 2026 in Review

Easterly Investment Partners increased its Pacira BioSciences (PCRX) stake by 0.65% in Q2 2026, buying an estimated $51.2K and bringing the position to 337,019 shares worth $8.55M. The position accounts for 0.44% of the portfolio, ranked #47.

Easterly Investment Partners first reported a position in PCRX in Q3 2023 and has held it in 12 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Easterly Investment Partners held 337,019 shares of Pacira BioSciences worth $8.55M as of Q2 2026.
Easterly Investment Partners bought 2,165 Pacira BioSciences shares in Q2 2026, an estimated $51.2K.
Pacira BioSciences made up 0.44% of Easterly Investment Partners's portfolio in Q2 2026, its #47 holding.
Easterly Investment Partners first reported a position in Pacira BioSciences in Q3 2023 and has held it in 12 quarters since.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Easterly Investment Partners's 13F filing for Q2 2026, filed 23 Jul 2026.